# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
B. Riley Securities analyst Mayank Mamtani reiterates Novavax (NASDAQ:NVAX) with a Buy and lowers the price target from $25 ...
JP Morgan analyst Eric Joseph maintains Novavax (NASDAQ:NVAX) with a Underweight and raises the price target from $8 to $9.
Novavax reported Q2 2024 revenue of $415 million, missing estimates, with net income rising to $162 million. EPS increased to $...
- Conference Call
Novavax (NASDAQ:NVAX) reported quarterly earnings of $0.99 per share which missed the analyst consensus estimate of $1.64 by 39...
B. Riley Securities analyst Mayank Mamtani maintains Novavax (NASDAQ:NVAX) with a Buy and lowers the price target from $29 t...
Novavax shares are trading lower by 5.5% Thursday morning. Shares of several vaccine makers are trading lower after Moderna rev...